HK1201850A1 - Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy - Google Patents

Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy Download PDF

Info

Publication number
HK1201850A1
HK1201850A1 HK15102275.5A HK15102275A HK1201850A1 HK 1201850 A1 HK1201850 A1 HK 1201850A1 HK 15102275 A HK15102275 A HK 15102275A HK 1201850 A1 HK1201850 A1 HK 1201850A1
Authority
HK
Hong Kong
Prior art keywords
peptides
hydrochloride salt
peptide
immunotherapy
combination
Prior art date
Application number
HK15102275.5A
Other languages
English (en)
Chinese (zh)
Inventor
Paul Laidler
Imre Farkas
Original Assignee
Circassia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Limited filed Critical Circassia Limited
Publication of HK1201850A1 publication Critical patent/HK1201850A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK15102275.5A 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy HK1201850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1208293.9 2012-05-11
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
PCT/GB2013/051201 WO2013167897A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Publications (1)

Publication Number Publication Date
HK1201850A1 true HK1201850A1 (en) 2015-09-11

Family

ID=46396890

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102275.5A HK1201850A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Country Status (17)

Country Link
US (1) US9657061B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2847209B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5982562B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150014955A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104428311B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013257784A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014028130A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2873120A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201492068A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB201208293D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1201850A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL235388A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014013394A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201407446TA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013167897A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201408290B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MY199068A (en) 2014-12-23 2023-10-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
ES2991207T3 (es) 2015-03-27 2024-12-02 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para su uso en inmunoterapia contra diversos tumores (SEQ ID 253 - Rad54b)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874522B2 (ja) * 2001-12-05 2012-02-15 サーカッシア リミテッド 免疫療法および系
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EP2397154B1 (en) * 2007-08-15 2015-07-15 Circassia Limited Peptides for desensibilization against allergens
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
BR112012025047A2 (pt) * 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas

Also Published As

Publication number Publication date
SG11201407446TA (en) 2015-03-30
MX2014013394A (es) 2015-02-04
US20150110820A1 (en) 2015-04-23
WO2013167897A1 (en) 2013-11-14
EA201492068A1 (ru) 2015-03-31
JP5982562B2 (ja) 2016-08-31
EP2847209B8 (en) 2020-10-07
GB201208293D0 (en) 2012-06-20
GB2517354A (en) 2015-02-18
EP2847209A1 (en) 2015-03-18
IN2014DN09367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-17
GB201421491D0 (en) 2015-01-14
JP2015517484A (ja) 2015-06-22
US9657061B2 (en) 2017-05-23
CA2873120A1 (en) 2013-11-14
CN104428311A (zh) 2015-03-18
CN104428311B (zh) 2019-11-01
IL235388A (en) 2016-06-30
EP2847209B1 (en) 2020-08-05
KR20150014955A (ko) 2015-02-09
BR112014028130A2 (pt) 2017-08-15
AU2013257784A1 (en) 2014-11-20
ZA201408290B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
HK1201850A1 (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
WO2013000922A9 (en) Ccr2 antagonist peptides
PL2547692T3 (pl) Pochodne peptydów, ich wytwarzanie i ich zastosowania
ZA201308251B (en) Amino acid sequence presenting fusion polypeptide and its use
UA118167C2 (uk) Пептид та його застосування
GB201206559D0 (en) Polypeptide
IL228813A0 (en) Amino acid sequences directed against a17-il, f17-il and/or f/a17-il and polypeptides containing them
MX2020010399A (es) 3-epimerasa.
IL223285A0 (en) Cell-penetrating peptides and uses therof
HK1205746A1 (en) Interleukin-10 polypeptide conjugates and their uses
CN104540941A8 (zh) 获得肽的方法
WO2010129895A3 (en) Cd133 epitopes
WO2013078217A3 (en) Anti-microbial peptides and methods of use thereof
WO2014136064A3 (en) Immunogenic fusion polypeptides
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
JP2010265269A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ706884A (en) Fc gamma receptor iib variants
EA033145B1 (ru) Применение полученных из pedf пептидов в стимуляции регенерации мышцы, регенерации сухожилия или артериогенеза
NZ629130A (en) Tfpi inhibitors and methods of use
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
PL3346273T3 (pl) Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie
EP3263123A3 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
WO2013156458A8 (en) Reduction of formation of amidated amino acids in cell lines for protein expression